Syndax Revenue Rises to $83.3 Million

Syndax Pharmaceuticals reported quarterly revenue of $83.298 million and a net loss of $49.433 million for the period ended September 30, 2026.

Updated on Nov. 3, 2026 in Economic Indicators

Bold flat-color editorial illustration of a single amber liquid flask on a steel plinth against a deep navy field, evoking pharmaceutical revenue growth. — Syndax Pharmaceuticals reported quarterly revenue of $83.3 million for the period ended September 30, up from $45.9 million a year earlier, while its net loss narrowed to $49.4 million. AI Illustration. Upload story photo >

Syndax Pharmaceuticals reported $83.298 million in revenue for the quarter ended September 30, 2026, up from $45.871 million a year earlier. The company also posted a net loss attributable to common stockholders of $49.433 million, or $0.55 per share.

Why it matters

The results show revenue growth for the Cancer therapy developer while its net loss narrowed compared with the prior-year quarter. The figures offer a snapshot of how its commercial and collaboration income is tracking across the United States biotech sector.

Product revenue from Revuforj totaled $60.743 million and collaboration revenue from the Niktimvo collaboration was $22.555 million, against total revenue of $83.298 million for the quarter ended September 30, 2026. Net loss per share narrowed to $0.55 from $0.70 a year earlier, and the source does not address forward guidance.

The players

Syndax Pharmaceuticals

Syndax Pharmaceuticals is a biopharmaceutical company that develops cancer therapies, including the drug Revuforj.

The details

Revenue consisted of product revenue tied to Revuforj and collaboration revenue from the Niktimvo collaboration. Syndax Pharmaceuticals, which develops cancer therapies, announced the results on November 2, 2026.

The reported quarter ended September 30, 2026.
The prior-year comparison quarter ended September 30, 2025.
Syndax announced the quarterly results on November 2, 2026.

Market Landscape

Quarterly results from individual oncology developers like Syndax provide a company-level view of commercial uptake in the cancer drug segment. The extraction does not provide comparison to named industry benchmarks or policy references.

For investors and shareholders, the narrower per-share loss reflects a smaller gap between expenses and income in the period reported. The figures do not directly change prices or household budgets for most readers.

The takeaway

Syndax's quarter shows revenue growing from both its approved product and a collaboration, while losses per share narrowed. Readers tracking biotech finances should watch future filings for guidance on whether this trend continues.